Effectiveness of Levonorgestrel Releasing Intrauterine System in Perimenopausal Women with Heavy Menstrual Bleeding: A Prospective Study at a Teaching Hospital in India
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: To evaluate the effect of levonorgestrel-releasing intrauterine system (LNG-IUS) on heavy menstrual bleeding in perimenopausal women.Methods: This was a prospective, observational clinical study conducted on 42 perimenopausal women with heavy menstrual bleeding who met the study eligibility criteria. LNG-IUS was inserted in the postmenstrual phase following baseline evaluation. The patients were followed up at the 4, 12, and 24 weeks. Pictorial blood assessment chart (PBAC) score, hemoglobin and serum ferritin levels, and endometrial thickness were assessed before insertion and during the follow-up visits. Results: Two patients (4.8%) were lost to follow-up, three patients (7.1%) opted for hysterectomy, two women (4.8%) experienced spontaneous expulsion and 35 (83.3%) women continued the usage. Menstrual blood loss assessed using the median PBAC score (interquartile range) significantly reduced (P < 0.001) from the pre-insertion level of 280 (246–306) to 124 (60–200) at 4 weeks to 45 (34–76) at 12 weeks and further to 32 (20–50) at the end of 24 weeks. Simultaneously, a significant (P < 0.001) improvement in the mean hemoglobin and serum ferritin levels and a significant (P < 0.001) decrease in endometrial thickness were observed. The most common side effect was spotting (50.0%) and vaginal discharge (38.1%).Conclusions: LNG-IUS causes a remarkable reduction in menstrual blood loss and marked improvement in dysmenorrhea. It also reduces anemia by improving the hemoglobin and ferritin levels. Thus, it can serve as an effective treatment option for heavy menstrual bleeding in perimenopausal women and prevent the need for a hysterectomy.
Abstract
Objectives: To evaluate the effect of levonorgestrel-releasing intrauterine system (LNG-IUS) on heavy menstrual bleeding in perimenopausal women.Methods: This was a prospective, observational clinical study conducted on 42 perimenopausal women with heavy menstrual bleeding who met the study eligibility criteria. LNG-IUS was inserted in the postmenstrual phase following baseline evaluation. The patients were followed up at the 4, 12, and 24 weeks. Pictorial blood assessment chart (PBAC) score, hemoglobin and serum ferritin levels, and endometrial thickness were assessed before insertion and during the follow-up visits. Results: Two patients (4.8%) were lost to follow-up, three patients (7.1%) opted for hysterectomy, two women (4.8%) experienced spontaneous expulsion and 35 (83.3%) women continued the usage. Menstrual blood loss assessed using the median PBAC score (interquartile range) significantly reduced (P < 0.001) from the pre-insertion level of 280 (246–306) to 124 (60–200) at 4 weeks to 45 (34–76) at 12 weeks and further to 32 (20–50) at the end of 24 weeks. Simultaneously, a significant (P < 0.001) improvement in the mean hemoglobin and serum ferritin levels and a significant (P < 0.001) decrease in endometrial thickness were observed. The most common side effect was spotting (50.0%) and vaginal discharge (38.1%).Conclusions: LNG-IUS causes a remarkable reduction in menstrual blood loss and marked improvement in dysmenorrhea. It also reduces anemia by improving the hemoglobin and ferritin levels. Thus, it can serve as an effective treatment option for heavy menstrual bleeding in perimenopausal women and prevent the need for a hysterectomy.
참고문헌 (28)
- Munro MG, "FIGO classification system(PALM-COEIN)for causes of abnormal uterine bleeding in nongravid women of reproductive age", Int J Gynaecol Obstet, 113, pp.3~13 (2011)
- Higham JM, "Assessment of menstrual blood loss using a pictorial chart", Br J Obstet Gynaecol, 97, pp.734~739 (1990)
- Davies J, "Heavy menstrual bleeding : an update on management", Thromb Res, 151(Suppl 1), pp.S70~S77 (2017)
- Maybin JA, "Medical management of heavy menstrual bleeding", Womens Health(Lond), 12, pp.27~34 (2016)
- Wright RC, "Hysterectomy : past, present, and future", Obstet Gynecol, 33, pp.560~563 (1969)
- Gupta J, "Levonorgestrel intrauterine system versus medical therapy for menorrhagia", N Engl J Med, 368, pp.128~137 (2013)
- Stewart A, "The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia : a systematic review", BJOG, 108, pp.74~86 (2001)
- Joo Jong-Kil, "Levonorgestrel-Releasing Intrauterine System Use in Perimenopausal Women", 대한폐경학회지, 27(2), pp.49~57 (2021), 대한폐경학회[DOI]
- Kaunitz AM, "Levonorgestrel-releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels", Contraception, 86, pp.452~457 (2012)
- Kriplani A, "Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia", Int J Gynaecol Obstet, 97, pp.190~194 (2007)
- Desai RM, "Efficacy of levonorgestrel releasing intrauterine system for the treatment of menorrhagia due to benign uterine lesions in perimenopausal women", J Midlife Health, 3, pp.20~23 (2012)
- Prager S, "The levonorgestrel intrauterine system in nulliparous women", Contraception, 75(6 Suppl), pp.S12~S15 (2007)
- Dhamangaonkar PC, "Levonorgestrel intrauterine system(Mirena) : an emerging tool for conservative treatment of abnormal uterine bleeding", J Midlife Health, 6, pp.26~30 (2015)
- Heikinheimo O, "The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women : a 5-year follow-up study", Am J Obstet Gynecol, 204, pp.126.e1~126.e4 (2011)
- Lehtovirta P, "Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women", Contraception, 75, pp.37~39 (2007)
- Rogovskaya S, "Effect of a levonorgestrel intrauterine system on women with type 1 diabetes : a randomized trial", Obstet Gynecol, 105, pp.811~815 (2005)
- Grigoryan OR, "Contraception in perimenopausal women with diabetes mellitus", Gynecol Endocrinol, 22, pp.198~206 (2006)
- Lukes AS, "Use of the levonorgestrelreleasing intrauterine system in women with hemostatic disorders", Fertil Steril, 90, pp.673~677 (2008)
- Chi C, "Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders : long-term follow-up", Contraception, 83, pp.242~247 (2011)
- Park DS, "Clinical experiences of the levonorgestrel-releasing intrauterine system in patients with large symptomatic adenomyosis", Taiwan J Obstet Gynecol, 54, pp.412~415 (2015)
- Kriplani A, "Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma", Int J Gynaecol Obstet, 116, pp.35~38 (2012)
- Soysal S, "The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia : a prospective controlled trial", Gynecol Obstet Invest, 59, pp.29~35 (2005)
- Endrikat J, "The levonorgestrel-releasing intrauterine system provides a reliable, long-term treatment option for women with idiopathic menorrhagia", Arch Gynecol Obstet, 285, pp.117~121 (2012)
- Tang GW, "Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women : efficacy versus acceptability", Contraception, 51, pp.231~235 (1995)
- Sayed GH, "A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroidrelated menorrhagia", Int J Gynaecol Obstet, 112, pp.126~130 (2011)
- Sheng J, "The LNG-IUS study on adenomyosis : a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis", Contraception, 79, pp.189~193 (2009)
- Cho S, "Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis", Am J Obstet Gynecol, 198, pp.373.e1~373.e7 (2008)
- Stéphanie R, "Endometrial vessel maturation in women exposed to levonorgestrel-releasing intrauterine system for a short or prolonged period of time", Hum Reprod, 22, pp.3084~3091 (2007)